Thyme Care Raises $125 Million and Launches Oncology Venture Parent

Key Takeaways

• Thyme Care secured over $125 million in Series E financing while operating profitably and generating positive free cash flow.
• The newly formed Thyme Companies will develop independent businesses targeting biosimilar adoption and decentralized clinical trial enrollment.
• Thyme Care now serves 8 million covered lives and manages over $5 billion in annual oncology spending nationwide.

Thyme Care has secured over $125 million in Series E financing, giving the value-based oncology care business additional capital to expand nationally and pursue a broader operating model. The transaction pushes Thyme Care's valuation above $2 billion, according to CNBC.

The financing arrives with Thyme Care already profitable and producing positive free cash flow, an uncommon position among venture-backed healthcare technology businesses pursuing national scale. Its oncology navigation platform and care teams now reach 8 million covered lives across all 50 states. Thyme Care also manages over $5 billion in annual oncology spending.

At the center of the model are oncology-trained care teams, predictive risk software and relationships with community oncology practices. Thyme Care operates within payer risk contracts, giving it a financial incentive to improve care coordination while reducing avoidable spending. According to Thyme Care, the approach has lowered the total cost of care by between 5% and 10%.

Those savings remain a company-reported result, so payers and provider groups will still want to examine performance across populations, cancer types and contract structures. But the scale matters. Managing billions of dollars in oncology spending gives Thyme Care access to patterns that can help identify high-risk patients, gaps in care and potentially avoidable utilization.

Navigation is no longer the organization's sole operational focus. Thyme Care has established Thyme Companies, a parent entity intended to incubate and scale independent businesses focused on stubborn structural problems in cancer care. The first business unit is expected to launch later in 2026.

One early focus is biosimilar adoption. Thyme Companies plans to develop software and operating pathways that can help providers use lower-cost biosimilar therapies more frequently when clinically appropriate. For commercial insurers and Medicare Advantage plans, even incremental changes in utilization could matter when applied across large oncology populations.

Still, technology is only part of that equation. Biosimilar uptake can be affected by provider workflows, reimbursement incentives, formulary decisions and patient communication. Can a dedicated business coordinate those moving parts more effectively than a navigation platform alone? Thyme Companies is structured to test that proposition without forcing every new product into Thyme Care's core operating model.

The second development area is decentralized clinical trial accrual. Thyme Companies plans to build workflow and data tools that match community-based cancer patients with relevant studies and support enrollment. That could extend trial access beyond major academic medical centers, where geography and fragmented referral processes often limit participation.

Digital readiness among cancer patients may support that strategy. HHS and the Office of the National Coordinator for Health Information Technology reported that 76% of U.S. patients with a recent cancer diagnosis accessed online medical records or patient portals in 2024, compared with 65% of individuals nationally. Separately, an ESMO Open survey found that 93.3% of respondents reported increased use of digital health tools in oncology, with telehealth rated highly effective.

The expansion also changes Thyme Care's leadership structure. One co-founder will become executive chairman of Thyme Companies, leading corporate strategy and new-business development alongside the co-founding chief medical officer. The current CEO will remain in position at Thyme Care and continue overseeing its navigation and value-based care operations.

The chief medical officer will remain president of Thyme Care while contributing to the clinical roadmap for Thyme Companies. That overlapping role could help keep the new businesses connected to oncology practice rather than becoming detached technology products.

"People living with cancer have traditionally been left to coordinate care themselves and pay more along the way. Thyme Care is changing that experience and making it possible to improve cancer care while lowering costs," said the CEO of Morgan Health.

The larger test will be whether Thyme Companies can turn Thyme Care's operational experience into focused, commercially independent businesses. Biosimilar adoption and trial enrollment involve different buyers, incentives and workflows. Building them separately may give each more room to develop. It also makes Thyme Care's Series E more than a conventional expansion round: the capital is supporting a move from one oncology platform toward a portfolio of businesses aimed at different pressure points in cancer care.